|
|
Vaccine Detail
|
HyperAcute-Prostate Cancer Vaccine |
| Vaccine Information |
- Vaccine Name: HyperAcute-Prostate Cancer Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: alpha (1,3) galactosyl-epitopes (alpha-gal) (NCT00105053)
- Immunization Route: Intradermal injection (i.d.)
- Description: Patients with hormone refractory prostate cancer can be vaccinated with this vaccine composed of irradiated allogeneic prostate cancer cell lines (HAP-1 and HAP-2) that have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha (1,3) GT gene, a mouse gene that causes the production of a foreign pattern of protein-sugars on the cell surface. It is hoped that the immune response to the foreign substance will stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern, causing the tumor to remain stable or shrink.. The expression of the murine alpha (1,3) galactosyltransferase [alpha (1,3) GT] gene results in the cell surface expression of alpha (1,3) galactosyl-epitopes (alpha-gal) on membrane glycoproteins and glycolipids. (NCT00105053)
|
| Host Response |
|
|
| References |
NCT00105053: Vaccine Treatment for Hormone Refractory Prostate Cancer [https://clinicaltrials.gov/study/NCT00105053]
|
|
